A national study seeking more effective treatment for deadly metaplastic breast cancer has identified two inhibitor drugs with the potential to interrupt disease progression.

A national study seeking more effective treatment for deadly metaplastic breast cancer has identified two inhibitor drugs with the potential to interrupt disease progression.

Dr. Weickert will present Pacylex at the OBIO® Investment Summit and Early Technology Showcase February 5-7, 2025, at the Arcadian Court & Loft, Toronto Mr. Kamdar will present Pacylex at the PWMC ...

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated ...

Researchers from the University of Sharjah have identified a common herb, Artemisia herba-alba, as a potential natural ...

Artemisia herba-alba shows promise in combating colorectal cancer, offering new hope through its powerful medicinal ...

A common aromatic shrub that has served as traditional medicine for centuries could point the way toward innovative treatments for colorectal cancer ...

Scientists from the University of Sharjah have found that a naturally growing aromatic plant contains ingredients with the ...

A study published by the Journal of Traditional and Complementary Medicine and e-published by the U.S. National Library of ...

Below is a detailed analysis of the two drugs secured by Cosmos Health. Abstract #1: ESTERS OF STEROIDAL LACTAM AND BIS (2-CHLOROETHYL) AMINOPHENOXY PROPANOIC ACID DERIVATIVES; Patent International ...

Mutational load was low, although three patients (21%) displayed molecular events in relapse samples leading to PI3K/mTOR pathway hyperactivation. mTOR inhibition with everolimus obtained a sustained ...